Photodynamic therapy (PDT), which is the interaction of light with hematoporphyrin derivative (HPD or Photofrin II), is in clinical use in several areas of application. Currently, PDT is being used clinically for bronchial obstructions, carcinoma in situ of the bladder, and intraperitoneal and pleural tumors. Animal models were investigated and are being analyzed to assess the potential of using PDT for lung mesothelioma. Specially designed fiberoptic probes and introducers were manufactured for all cases, calibrated in terms of irradiance delivered to the tissue. Dosimetry for PDT is complex due to the variable irradiation levels within the tissue, the sequestering of HPD, and tissue oxygenation.
